This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Ultragenyx Faces Class Action Lawsuit
Business class action lawsuit

Ultragenyx Faces Class Action Lawsuit

Analysis based on 12 articles · First reported Feb 12, 2026 · Last updated Mar 09, 2026

Sentiment
-20
Attention
2
Articles
12
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Ultragenyx could lead to a decline in its stock price due to allegations of misleading statements regarding its drug setrusumab. This event highlights the risks associated with pharmaceutical development and corporate disclosures.

Pharmaceuticals Biotechnology Legal Services
Event Summary

The Portnoy Law Firm has advised investors of Ultragenyx, Inc. of a class action lawsuit. The lawsuit alleges that Ultragenyx made false and misleading statements between August 3, 2023, and December 26, 2025, regarding its drug setrusumab and its Phase III Orbit study. Specifically, the complaint claims that Ultragenyx created a false impression of reliable information about setrusumab's effects on Osteogenesis Imperfecta patients and minimized the risk of the Phase III Orbit study failing to achieve a statistically significant reduction in annualized fracture rate. Investors have until April 6, 2026, to file a lead plaintiff motion.

Key Actions
100 Ultragenyx allegedly made false and misleading statements
90 Portnoy Law Firm advised investors of a class action lawsuit Ultragenyx
Entities Involved
stock
Ultragenyx
Ultragenyx is facing a class action lawsuit alleging that it made false and misleading statements regarding its drug setrusumab and its Phase III Orbit study. This could negatively impact its stock price and reputation.
Importance 100 Sentiment -50
priv
Portnoy Law Firm
The Portnoy Law Firm is advising investors of Ultragenyx about the class action lawsuit and is representing them in pursuing claims. This event provides business for the firm.
Importance 80 Sentiment 50
per
Lesley F. Portnoy
Lesley F. Portnoy is an attorney at the Portnoy Law Firm and is encouraging investors to contact her regarding the Ultragenyx class action lawsuit.
Importance 60 Sentiment 40
exch
Nasdaq
Nasdaq is the stock exchange where Ultragenyx's shares are traded. The lawsuit may cause fluctuations in the stock price on this exchange.
Importance 10 Sentiment 0
Relationships
Lesley F. Portnoy related ↔ Portnoy Law Firm
Ultragenyx related ↔ Portnoy Law Firm
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.